Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 2C11H13Cl2N5.C10H8O6S2 |
| Molecular Weight | 860.618 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)N=C(N)N=C(N)N1C2=CC=C(Cl)C(Cl)=C2.CC3(C)N=C(N)N=C(N)N3C4=CC=C(Cl)C(Cl)=C4.OS(=O)(=O)C5=CC=CC6=C(C=CC=C56)S(O)(=O)=O
InChI
InChIKey=DNXIQHJNRRKCOD-UHFFFAOYSA-N
InChI=1S/2C11H13Cl2N5.C10H8O6S2/c2*1-11(2)17-9(14)16-10(15)18(11)6-3-4-7(12)8(13)5-6;11-17(12,13)9-5-1-3-7-8(9)4-2-6-10(7)18(14,15)16/h2*3-5H,1-2H3,(H4,14,15,16,17);1-6H,(H,11,12,13)(H,14,15,16)
Chlorproguanil is a biguanide. Chlorproguanil is active against P. falciparum and P. malariae. Chlorproguanil acts by inhibition of dihydrofolate reductase after cytochrome P450-catalysed cyclization. Chlorproguanil combined with dapsone was developing for the treatment of falciparum malaria. The anti-malarial combination chloroproguanil and dapsone has been withdrawn following demonstration of post-treatment haemolytic anaemia in glucose-6-phosphate dehydrogenase (G6PD) deficient patients in a phase III
clinical trial.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6056-10-6
Created by
admin on Fri Dec 15 15:14:42 GMT 2023 , Edited by admin on Fri Dec 15 15:14:42 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
134824506
Created by
admin on Fri Dec 15 15:14:42 GMT 2023 , Edited by admin on Fri Dec 15 15:14:42 GMT 2023
|
PRIMARY | |||
|
Q7FW585AFF
Created by
admin on Fri Dec 15 15:14:42 GMT 2023 , Edited by admin on Fri Dec 15 15:14:42 GMT 2023
|
PRIMARY |
